Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-762
- Development stage
- Preclinical
- Lead developer
- University Hospital Halle (Saale)
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
anti-miR-762 is an antisense oligonucleotide (ASO) designed to inhibit the activity of microRNA-762 (miR-762). Research conducted at University Hospital Halle indicates that miR-762 is significantly upregulated following myocardial infarction (MI), where it impairs tissue repair processes. By antagonizing miR-762, this therapeutic candidate enhances endothelial cell migration and angiogenesis while reducing apoptosis. Mechanistically, the inhibition of miR-762 leads to the downregulation of CMPK2 and XAF1 protein levels, acting through the IFNγ-JAK-STAT signaling pathway. Preliminary data also suggest that anti-miR-762 may modulate aortic fibroblast activity, potentially leading to decreased scar formation and improved cardiac regeneration post-MI.
- Other names
- miR-762 inhibitormiR762 inhibitormiR 762 inhibitorantagomir-762antagomir762antagomir 762
02
Targets
CMPK2 (Cytidine/uridine monophosphate kinase 2)XAF1 (XIAP-associated factor 1)STAT1 (Signal transducer and activator of transcription protein 1)miR-762 (MicroRNA-762)IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on anti-miR-762.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-762.